Adele Salemme
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adele Salemme has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Anna Rita Togna
4 shared publicationsAlessia Provini
Dermaology Unit IDI-IRCCS, Rome, Italy
3 shared publications- Giovanni Di Zenzo
Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy
3 shared publications Biagio Didona
First Dermatologic Division, IDI-IRCCS, Rome, Italy
2 shared publicationsCinzia Mazzanti
First Dermatologic Division, IDI-IRCCS, Rome, Italy
2 shared publications- Emanuele Cozzani
Department of Health Sciences, University of Genoa, Genoa, Italy
2 shared publications
Latest Publications
- Open Access
- 10 February 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (6) , 1837-1841
Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients
Bullous pemphigoid (BP) is an autoimmune blistering disease that targets the haemidesmosomal proteins, mainly BP180. Extracellular vesicles (EVs) have been demonstrated to carry tissue-specific autoantigens in the setting of autoimmune diseases and transplant organ rejection; this phenomenon was demonstrated to have pathogenic implications in autoimmune diseases and to correlate with transplant rejection severity. The purpose of this study was to identify the presence of BP targeted autoantigens in blister fluid derived EVs. We isolated, by size exclusion chromatography, EVs derived from blisters of BP-patients and from suction blisters of healthy donors. EV characterization was performed by flow cytometry and nanoparticle tracking analysis. Western blot analysis was used to investigate the presence of autoantigens. A suspension enriched in EVs was efficiently obtained from blister fluid from patients and healthy donors. EV-enriched fractions were enriched in particles with a size distribution characterizing small-EVs (main peak was present at 94.5 nm). BP180 was found, by western blot analysis, in EVs derived from blister fluid of 3 out 6 BP patients and in none of EVs isolated from suction blister fluid of healthy donors. BP230 and Dsg1 were not detectable in EVs of any of the samples. No specific clinical characteristics seemed to correlate to the presence of BP180 in EVs. The discovery of BP180 in EVs derived from blister fluid might help understanding BP pathogenesis.
- 10 February 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (6) , 1837-1841
Open AccessPilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients
Bullous pemphigoid (BP) is an autoimmune blistering disease that targets the haemidesmosomal proteins, mainly BP180. Extracellular vesicles (EVs) have been demonstrated to carry tissue-specific autoantigens in the setting of autoimmune diseases and transplant organ rejection; this phenomenon was demonstrated to have pathogenic implications in autoimmune diseases and to correlate with transplant rejection severity. The purpose of this study was to identify the presence of BP targeted autoantigens in blister fluid derived EVs. We isolated, by size exclusion chromatography, EVs derived from blisters of BP-patients and from suction blisters of healthy donors. EV characterization was performed by flow cytometry and nanoparticle tracking analysis. Western blot analysis was used to investigate the presence of autoantigens. A suspension enriched in EVs was efficiently obtained from blister fluid from patients and healthy donors. EV-enriched fractions were enriched in particles with a size distribution characterizing small-EVs (main peak was present at 94.5 nm). BP180 was found, by western blot analysis, in EVs derived from blister fluid of 3 out 6 BP patients and in none of EVs isolated from suction blister fluid of healthy donors. BP230 and Dsg1 were not detectable in EVs of any of the samples. No specific clinical characteristics seemed to correlate to the presence of BP180 in EVs. The discovery of BP180 in EVs derived from blister fluid might help understanding BP pathogenesis.
- Open Access
- 10 June 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (12) , 1547-1549
Inverted‐U serration pattern: a novel clue for the diagnosis of anti‐laminin‐γ1 pemphigoid
- 10 June 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (12) , 1547-1549
Open AccessInverted‐U serration pattern: a novel clue for the diagnosis of anti‐laminin‐γ1 pemphigoid
- Open Access
- 29 February 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (2) , adv00070
Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype
Linear IgA bullous dermatosis (LABD) is characterized by presence of multiple IgA autoantibodies, an...
- 29 February 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (2) , adv00070
Open AccessAutoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype
Linear IgA bullous dermatosis (LABD) is characterized by presence of multiple IgA autoantibodies, an...
- 11 November 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (3) , E146-E148
Development of bullous pemphigoid in junctional epidermolysis bullosa
- 11 November 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (3) , E146-E148
Development of bullous pemphigoid in junctional epidermolysis bullosa
- 14 July 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (71) , 67232-67241
Evaluation of the efficacy of carbon nanotubes for delivering peptides into mitochondria
Mitochondrial (mt) diseases are devastating neurodegenerative pathologies due to mutations in nuclear or mt genes. Among mtDNA pathogenic mutations, more than one half have been identified in transfer RNA (tRNA) genes. These are responsible for a wide range of pathologies including myopathies, encephalopathies, cardiomyopathies and deafness for which no effective treatment is available at present. Therefore, new strategies to suppress their damaging effects are required to envisage therapeutic approaches for these diseases. Here we report data for carbon nanotube (CNT) derivatives showing that the conjugates bearing a specific peptide sequence are able to target the mitochondria in yeast and human monocyte cells while the control derivative without the peptide diffuses into the cytoplasm. Moreover the compounds do not affect cellular viability and cytotoxicity both in vitro and in vivo. Toxicity of the constructs is also assessed on the simple pluricellular model Caenorhabditis elegans.
- 14 July 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (71) , 67232-67241
Evaluation of the efficacy of carbon nanotubes for delivering peptides into mitochondria
Mitochondrial (mt) diseases are devastating neurodegenerative pathologies due to mutations in nuclear or mt genes. Among mtDNA pathogenic mutations, more than one half have been identified in transfer RNA (tRNA) genes. These are responsible for a wide range of pathologies including myopathies, encephalopathies, cardiomyopathies and deafness for which no effective treatment is available at present. Therefore, new strategies to suppress their damaging effects are required to envisage therapeutic approaches for these diseases. Here we report data for carbon nanotube (CNT) derivatives showing that the conjugates bearing a specific peptide sequence are able to target the mitochondria in yeast and human monocyte cells while the control derivative without the peptide diffuses into the cytoplasm. Moreover the compounds do not affect cellular viability and cytotoxicity both in vitro and in vivo. Toxicity of the constructs is also assessed on the simple pluricellular model Caenorhabditis elegans.
- 1 January 2016
- Published by Elsevier in Brain Research Bulletin
- Vol. 120, 151-158
Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells
- 1 January 2016
- Published by Elsevier in Brain Research Bulletin
- Vol. 120, 151-158
Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells
- Open Access
- 1 January 2014
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 37 (1) , 60-66
4-Methylcoumarin Derivatives with Anti-inflammatory Effects in Activated Microglial Cells
Inflammation contributes to the pathogenesis of neurodegenerative diseases and anti-inflammatory compounds may have a role in prevention or treatment of these pathologies. 4-Methylcoumarins are effective antioxidants with anti-inflammatory properties. In this study, the inhibitory effects of two 4-methylcoumarin derivatives, 7,8-dihydroxy-3-ethoxycarbonylmethyl-4-methylcoumarin (DHEMC) and 7,8-diacetoxy-3-ethoxycarbonylmethyl-4-methylcoumarin (DAEMC) were examined on the inflammatory processes induced by lipopolysaccharide (LPS) in activated primary rat microglial cultures. LPS-induced production of nitric oxide (NO, measured by Griess method) and other pro-inflammatory mediators, thromboxane (TX) B2 and prostaglandin (PG) E2 (both determined by radioimmunoassay (RIA)), as well as tumor necrosis factor (TNF)-α (determined by enzyme-linked immunosorbent assay (ELISA)) were inhibited in the presence of 100 µM DHEMC and DAEMC. DAEMC was able to significantly inhibit NO, TXB2 and TNF-α production also at 50 µM. Both compounds at 100 µM significantly lowered cyclooxygenase-2 (COX-2) protein expression in LPS-stimulated microglial cells measured by Western blot, but only DAEMC showed an inhibitory effect on inducible nitric oxide synthase (iNOS) protein expression at 100 µM. In conclusion, our findings show that 4-methylcoumarin derivatives can modulate inflammatory pathways in microglial cells, probably by acting at the protein expression level.
- 1 January 2014
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 37 (1) , 60-66
Open Access4-Methylcoumarin Derivatives with Anti-inflammatory Effects in Activated Microglial Cells
Inflammation contributes to the pathogenesis of neurodegenerative diseases and anti-inflammatory compounds may have a role in prevention or treatment of these pathologies. 4-Methylcoumarins are effective antioxidants with anti-inflammatory properties. In this study, the inhibitory effects of two 4-methylcoumarin derivatives, 7,8-dihydroxy-3-ethoxycarbonylmethyl-4-methylcoumarin (DHEMC) and 7,8-diacetoxy-3-ethoxycarbonylmethyl-4-methylcoumarin (DAEMC) were examined on the inflammatory processes induced by lipopolysaccharide (LPS) in activated primary rat microglial cultures. LPS-induced production of nitric oxide (NO, measured by Griess method) and other pro-inflammatory mediators, thromboxane (TX) B2 and prostaglandin (PG) E2 (both determined by radioimmunoassay (RIA)), as well as tumor necrosis factor (TNF)-α (determined by enzyme-linked immunosorbent assay (ELISA)) were inhibited in the presence of 100 µM DHEMC and DAEMC. DAEMC was able to significantly inhibit NO, TXB2 and TNF-α production also at 50 µM. Both compounds at 100 µM significantly lowered cyclooxygenase-2 (COX-2) protein expression in LPS-stimulated microglial cells measured by Western blot, but only DAEMC showed an inhibitory effect on inducible nitric oxide synthase (iNOS) protein expression at 100 µM. In conclusion, our findings show that 4-methylcoumarin derivatives can modulate inflammatory pathways in microglial cells, probably by acting at the protein expression level.
- 1 December 2013
- Published by Elsevier in Neuropharmacology
- Vol. 75, 391-398
In vitro morphine metabolism by rat microglia
- 1 December 2013
- Published by Elsevier in Neuropharmacology
- Vol. 75, 391-398
In vitro morphine metabolism by rat microglia